Atea Pharmaceuticals (AVIR)
Atea Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
3.1M
Short interest
settlement 2026-10-15
10.7
Days to cover
-15.2 days vs prior
68.6%
Short share of volume
2026-11-02
1,237
Fails to deliver
settlement 2026-09-18
Wed 11 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in AVIR is 3,070,296 shares, down 4,559,779 shares over the last month. Over the last 48 readings it ranged from 2,590,497 shares (31 October 2024) to 7,994,672 shares (13 March 2026). The latest reading sits at the bottom of that range. At the reported average volume of 287K shares a day that is 10.7 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/avir" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 3,070,296 | -61.1% | 287,224 | 10.69 |
| 2026-09-30 | 7,886,499 | +3.4% | 304,918 | 25.86 |
| 2026-09-15 | 7,630,075 | -0.4% | 279,462 | 27.30 |
| 2026-08-31 | 7,663,720 | -0.1% | 186,207 | 41.16 |
| 2026-08-14 | 7,669,615 | +1.9% | 288,345 | 26.60 |
| 2026-07-31 | 7,528,225 | -3.0% | 417,474 | 18.03 |
| 2026-07-15 | 7,757,331 | +11.0% | 340,925 | 22.75 |
| 2026-06-30 | 6,990,933 | -1.2% | 435,957 | 16.04 |
| 2026-06-15 | 7,073,864 | -6.0% | 244,779 | 28.90 |
| 2026-05-29 | 7,527,444 | -0.9% | 314,525 | 23.93 |
| 2026-05-15 | 7,594,069 | +1.4% | 384,814 | 19.73 |
| 2026-04-30 | 7,488,888 | -2.6% | 262,834 | 28.49 |
| 2026-04-15 | 7,686,253 | +1.3% | 345,606 | 22.24 |
| 2026-03-31 | 7,586,717 | -5.1% | 487,449 | 15.56 |
| 2026-03-13 | 7,994,672 | +1.4% | 809,922 | 9.87 |
| 2026-02-27 | 7,880,520 | +2.1% | 388,565 | 20.28 |
| 2026-02-13 | 7,720,658 | +0.7% | 522,862 | 14.77 |
| 2026-01-30 | 7,664,024 | +5.0% | 641,762 | 11.94 |
| 2026-01-15 | 7,302,088 | +5.5% | 353,055 | 20.68 |
| 2025-12-31 | 6,924,486 | +1.7% | 421,391 | 16.43 |
| 2025-12-15 | 6,807,812 | +0.9% | 326,402 | 20.86 |
| 2025-11-28 | 6,745,446 | -1.6% | 390,551 | 17.27 |
| 2025-11-14 | 6,855,045 | +7.0% | 456,273 | 15.02 |
| 2025-10-31 | 6,403,948 | +5.8% | 391,818 | 16.34 |
| 2025-10-15 | 6,051,471 | +0.7% | 560,271 | 10.80 |
| 2025-09-30 | 6,009,591 | -2.1% | 283,026 | 21.23 |
| 2025-09-15 | 6,137,935 | +4.7% | 168,498 | 36.43 |
| 2025-08-29 | 5,860,157 | +19.8% | 348,079 | 16.84 |
| 2025-08-15 | 4,893,177 | +9.8% | 324,195 | 15.09 |
| 2025-07-31 | 4,458,439 | +2.8% | 425,610 | 10.48 |
| 2025-07-15 | 4,335,865 | +13.8% | 355,191 | 12.21 |
| 2025-06-30 | 3,809,867 | +14.8% | 441,868 | 8.62 |
| 2025-06-13 | 3,319,297 | +8.6% | 404,750 | 8.20 |
| 2025-05-30 | 3,056,039 | -5.8% | 385,743 | 7.92 |
| 2025-05-15 | 3,244,483 | +6.4% | 483,425 | 6.71 |
| 2025-04-30 | 3,048,428 | +2.7% | 566,275 | 5.38 |
| 2025-04-15 | 2,967,236 | -1.5% | 315,897 | 9.39 |
| 2025-03-31 | 3,011,739 | +3.3% | 246,939 | 12.20 |
| 2025-03-14 | 2,914,995 | +1.7% | 293,689 | 9.93 |
| 2025-02-28 | 2,867,436 | -2.8% | 287,885 | 9.96 |
| 2025-02-14 | 2,948,699 | +0.1% | 333,085 | 8.85 |
| 2025-01-31 | 2,945,809 | +3.5% | 381,620 | 7.72 |
| 2025-01-15 | 2,846,135 | +2.6% | 479,680 | 5.93 |
| 2024-12-31 | 2,773,596 | -12.8% | 672,467 | 4.12 |
| 2024-12-13 | 3,180,399 | +21.9% | 372,489 | 8.54 |
| 2024-11-29 | 2,608,626 | -1.1% | 153,416 | 17.00 |
| 2024-11-15 | 2,636,564 | +1.8% | 214,307 | 12.30 |
| 2024-10-31 | 2,590,497 | -1.5% | 135,839 | 19.07 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of AVIR volume is 68.6%, up 5.7 points over the last five sessions. Over the last 30 readings it ranged from 39.7% (27 October 2026) to 84.2% (23 September 2026). The latest reading is 7.0 points above the 30-session average of 61.7%, on 104K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 71K | 104K | 68.6% | 0 |
| 2026-10-30 | 34K | 62K | 54.7% | 0 |
| 2026-10-29 | 47K | 76K | 61.6% | 0 |
| 2026-10-28 | 47K | 88K | 53.3% | 0 |
| 2026-10-27 | 24K | 61K | 39.7% | 0 |
| 2026-10-26 | 52K | 83K | 62.9% | 0 |
| 2026-10-23 | 70K | 105K | 66.1% | 0 |
| 2026-10-22 | 50K | 86K | 57.9% | 0 |
| 2026-10-21 | 57K | 139K | 41.0% | 5 |
| 2026-10-20 | 35K | 70K | 50.8% | 500 |
| 2026-10-19 | 96K | 159K | 60.3% | 50 |
| 2026-10-16 | 46K | 76K | 61.4% | 505 |
| 2026-10-15 | 45K | 70K | 65.0% | 20 |
| 2026-10-14 | 83K | 135K | 61.4% | 0 |
| 2026-10-13 | 53K | 82K | 64.2% | 0 |
| 2026-10-12 | 39K | 58K | 66.4% | 0 |
| 2026-10-09 | 25K | 34K | 73.0% | 0 |
| 2026-10-08 | 55K | 83K | 66.1% | 0 |
| 2026-10-07 | 27K | 54K | 50.3% | 0 |
| 2026-10-06 | 40K | 61K | 66.1% | 1 |
| 2026-10-05 | 40K | 83K | 47.9% | 150 |
| 2026-10-02 | 56K | 77K | 72.2% | 9,061 |
| 2026-10-01 | 63K | 108K | 58.1% | 0 |
| 2026-09-30 | 25K | 59K | 42.4% | 0 |
| 2026-09-29 | 75K | 96K | 78.4% | 20 |
| 2026-09-28 | 51K | 73K | 70.2% | 1 |
| 2026-09-25 | 68K | 103K | 65.8% | 0 |
| 2026-09-24 | 43K | 70K | 61.4% | 1 |
| 2026-09-23 | 63K | 75K | 84.2% | 0 |
| 2026-09-22 | 60K | 77K | 78.3% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 18 September 2026, the fails-to-deliver balance in AVIR is 1,237 shares, up 1,157 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (2 June 2026) to 25,512 shares (23 March 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-18 | 1,237 | $5.26 | $7K |
| 2026-09-10 | 80 | $5.27 | $422 |
| 2026-07-23 | 2 | $4.81 | $10 |
| 2026-07-22 | 72 | $4.87 | $351 |
| 2026-07-01 | 164 | $4.65 | $763 |
| 2026-06-15 | 3,494 | $4.49 | $16K |
| 2026-06-02 | 1 | $4.38 | $4 |
| 2026-05-27 | 134 | $4.53 | $607 |
| 2026-04-23 | 294 | $5.61 | $2K |
| 2026-04-14 | 2 | $5.71 | $11 |
| 2026-04-02 | 18,501 | $5.65 | $105K |
| 2026-03-25 | 6,329 | $5.33 | $34K |
| 2026-03-24 | 16,426 | $5.57 | $91K |
| 2026-03-23 | 25,512 | $5.66 | $144K |
| 2026-03-17 | 9,915 | $6.05 | $60K |
| 2026-03-05 | 281 | $4.98 | $1K |
| 2026-02-19 | 24 | $4.60 | $110 |
| 2026-02-17 | 11,174 | $4.31 | $48K |
| 2026-02-09 | 5 | $4.15 | $21 |
| 2026-02-03 | 524 | $4.07 | $2K |
| 2026-02-02 | 524 | $4.24 | $2K |
| 2025-12-30 | 613 | $3.60 | $2K |
| 2025-12-18 | 652 | $3.18 | $2K |
| 2025-12-09 | 3 | $3.20 | $10 |
| 2025-12-03 | 221 | $3.00 | $663 |
| 2025-11-28 | 41 | $3.05 | $125 |
| 2025-11-26 | 963 | $3.03 | $3K |
| 2025-11-17 | 80 | $2.96 | $237 |
| 2025-11-06 | 400 | $3.24 | $1K |
| 2025-10-23 | 128 | $3.28 | $420 |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for AVIR in the last 90 days. The most recent filings are listed below. Latest filing: Lucidi Bruno (Director) on 2026-06-18.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Lucidi Bruno | Director | Exercise or conversion | 30K | $0.00 | $0 | 142K |
| 2026-06-18 | BERGER FRANKLIN M | Director | Exercise or conversion | 30K | $0.00 | $0 | 536K |
| 2026-06-18 | DUNCAN BARBARA GAYLE | Director | Exercise or conversion | 30K | $0.00 | $0 | 92K |
| 2026-06-18 | Polsky Bruce | Director | Exercise or conversion | 30K | $0.00 | $0 | 125K |
| 2026-06-18 | Murphy Polly A. | Director | Exercise or conversion | 30K | $0.00 | $0 | 122K |
| 2026-06-18 | Adams Jerome M. | Director | Exercise or conversion | 30K | $0.00 | $0 | 92K |
| 2026-05-18 | Murphy Polly A. | Director | Buy | 6K | $4.17 | $25K | 92K |
| 2026-03-11 | Corcoran Andrea | See Remarks | Exercise or conversion | 60K | $1.24 | $74K | 824K |
| 2026-02-03 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Exercise or conversion | 300K | $1.24 | $372K | 768K |
| 2026-01-31 | Foster Wayne | EVP, Chief Accounting Officer | Exercise or conversion | 41K | price not stated in the filing | not stated | 91K |
| 2026-01-31 | Foster Wayne | EVP, Chief Accounting Officer | Tax withholding | 12K | $4.24 | $51K | 79K |
| 2026-01-31 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Exercise or conversion | 273K | price not stated in the filing | not stated | 574K |
| 2026-01-31 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Tax withholding | 106K | $4.24 | $450K | 468K |
| 2026-01-31 | Corcoran Andrea | See Remarks | Tax withholding | 16K | $4.24 | $68K | 764K |
| 2026-01-31 | Corcoran Andrea | See Remarks | Exercise or conversion | 55K | price not stated in the filing | not stated | 780K |
| 2026-01-31 | Hammond Janet MJ | Chief Development Officer | Tax withholding | 14K | $4.24 | $60K | 128K |
| 2026-01-31 | Hammond Janet MJ | Chief Development Officer | Exercise or conversion | 58K | price not stated in the filing | not stated | 142K |
| 2026-01-31 | Vavricka John | Chief Commercial Officer | Exercise or conversion | 42K | price not stated in the filing | not stated | 94K |
| 2026-01-31 | Vavricka John | Chief Commercial Officer | Tax withholding | 12K | $4.24 | $49K | 83K |
| 2026-01-31 | Horga Maria Arantxa | Chief Medical Officer | Exercise or conversion | 51K | price not stated in the filing | not stated | 112K |
| 2026-01-31 | Horga Maria Arantxa | Chief Medical Officer | Tax withholding | 16K | $4.24 | $68K | 96K |
| 2025-06-20 | Duncan Barbara Gayle | Director | Exercise or conversion | 30K | $0.00 | $0 | 63K |
| 2025-06-20 | Murphy Polly A. | Director | Exercise or conversion | 30K | $0.00 | $0 | 86K |
| 2025-06-20 | BERGER FRANKLIN M | Director | Exercise or conversion | 30K | $0.00 | $0 | 506K |
| 2025-06-20 | Polsky Bruce | Director | Exercise or conversion | 30K | $0.00 | $0 | 95K |
| 2025-06-20 | Lucidi Bruno | Director | Exercise or conversion | 30K | $0.00 | $0 | 113K |
| 2025-06-20 | Adams Jerome M. | Director | Exercise or conversion | 30K | $0.00 | $0 | 63K |
| 2025-05-18 | Murphy Polly A. | Director | Buy | 6K | $4.17 | $25K | 92K |
| 2025-01-31 | Foster Wayne | EVP, Chief Accounting Officer | Tax withholding | 12K | $3.06 | $37K | 50K |
| 2025-01-31 | Foster Wayne | EVP, Chief Accounting Officer | Grant | 8K | price not stated in the filing | not stated | 62K |
| 2025-01-31 | Foster Wayne | EVP, Chief Accounting Officer | Exercise or conversion | 33K | price not stated in the filing | not stated | 54K |
| 2025-01-31 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Tax withholding | 89K | $3.06 | $271K | 301K |
| 2025-01-31 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Exercise or conversion | 173K | price not stated in the filing | not stated | 290K |
| 2025-01-31 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Grant | 100K | price not stated in the filing | not stated | 390K |
| 2025-01-31 | Corcoran Andrea | See Remarks | Exercise or conversion | 44K | price not stated in the filing | not stated | 723K |
| 2025-01-31 | Corcoran Andrea | See Remarks | Grant | 11K | price not stated in the filing | not stated | 733K |
| 2025-01-31 | Corcoran Andrea | See Remarks | Tax withholding | 16K | $3.06 | $49K | 717K |
| 2025-01-31 | Horga Maria Arantxa | Chief Medical Officer | Exercise or conversion | 42K | price not stated in the filing | not stated | 67K |
| 2025-01-31 | Horga Maria Arantxa | Chief Medical Officer | Tax withholding | 16K | $3.06 | $49K | 61K |
| 2025-01-31 | Horga Maria Arantxa | Chief Medical Officer | Grant | 10K | price not stated in the filing | not stated | 77K |
| 2025-01-31 | Hammond Janet MJ | Chief Development Officer | Grant | 11K | price not stated in the filing | not stated | 96K |
| 2025-01-31 | Hammond Janet MJ | Chief Development Officer | Tax withholding | 14K | $3.06 | $43K | 81K |
| 2025-01-31 | Hammond Janet MJ | Chief Development Officer | Exercise or conversion | 47K | price not stated in the filing | not stated | 84K |
| 2025-01-31 | Vavricka John | Chief Commercial Officer | Tax withholding | 12K | $3.06 | $35K | 52K |
| 2025-01-31 | Vavricka John | Chief Commercial Officer | Exercise or conversion | 33K | price not stated in the filing | not stated | 55K |
| 2025-01-31 | Vavricka John | Chief Commercial Officer | Grant | 9K | price not stated in the filing | not stated | 64K |
| 2025-01-16 | BERGER FRANKLIN M | Director | Buy | 10K | $3.36 | $34K | 477K |
| 2025-01-15 | BERGER FRANKLIN M | Director | Buy | 15K | $3.19 | $48K | 467K |
| 2024-12-10 | BERGER FRANKLIN M | Director | Sell | 360K | $2.85 | $1.0M | 452K |
| 2024-09-19 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Sell | 2K | $4.00 | $7K | 5.9M |
| 2024-09-18 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Sell | 22K | $4.03 | $89K | 5.9M |
| 2024-09-17 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Sell | 34K | $4.05 | $137K | 5.9M |
| 2024-06-20 | Polsky Bruce | Director | Sell | 18K | $3.49 | $61K | 66K |
| 2024-06-16 | Adams Jerome M. | Director | Exercise or conversion | 33K | $0.00 | $0 | 33K |
| 2024-06-16 | Duncan Barbara Gayle | Director | Exercise or conversion | 33K | $0.00 | $0 | 33K |
| 2024-06-16 | BERGER FRANKLIN M | Director | Exercise or conversion | 33K | $0.00 | $0 | 812K |
| 2024-06-16 | Lucidi Bruno | Director | Exercise or conversion | 33K | $0.00 | $0 | 83K |
| 2024-06-16 | Polsky Bruce | Director | Exercise or conversion | 33K | $0.00 | $0 | 83K |
| 2024-06-16 | Murphy Polly A. | Director | Exercise or conversion | 33K | $0.00 | $0 | 56K |
| 2024-06-05 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Sell | 1K | $4.00 | $4K | 5.9M |
| 2024-02-01 | Hammond Janet MJ | Chief Development Officer | Sell | 14K | $3.84 | $54K | 35K |
| 2024-02-01 | Vavricka John | Chief Commercial Officer | Sell | 12K | $3.84 | $45K | 22K |
| 2024-02-01 | Foster Wayne | EVP, Chief Accounting Officer | Sell | 12K | $3.84 | $48K | 21K |
| 2024-02-01 | Horga Maria Arantxa | Chief Medical Officer | Sell | 16K | $3.84 | $61K | 26K |
| 2024-02-01 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Sell | 57K | $3.85 | $219K | 117K |
| 2024-02-01 | Corcoran Andrea | See Remarks | Sell | 16K | $3.84 | $61K | 670K |
| 2024-01-31 | Hammond Janet MJ | Chief Development Officer | Exercise or conversion | 47K | price not stated in the filing | not stated | 49K |
| 2024-01-31 | Vavricka John | Chief Commercial Officer | Exercise or conversion | 33K | price not stated in the filing | not stated | 33K |
| 2024-01-31 | Foster Wayne | EVP, Chief Accounting Officer | Exercise or conversion | 33K | price not stated in the filing | not stated | 33K |
| 2024-01-31 | Horga Maria Arantxa | Chief Medical Officer | Exercise or conversion | 42K | price not stated in the filing | not stated | 42K |
| 2024-01-31 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Exercise or conversion | 173K | price not stated in the filing | not stated | 173K |
| 2024-01-31 | Corcoran Andrea | See Remarks | Exercise or conversion | 44K | price not stated in the filing | not stated | 686K |
| 2022-11-14 | BERGER FRANKLIN M | Director | Sell | 16K | $5.16 | $83K | 778K |
| 2022-11-11 | BERGER FRANKLIN M | Director | Sell | 26K | $5.15 | $131K | 795K |
| 2021-12-20 | Murphy Polly A. | Director | Buy | 12K | $8.57 | $103K | 23K |
| 2020-11-03 | Vavricka John | Chief Commercial Officer | Conversion | 83K | price not stated in the filing | not stated | 83K |
| 2020-11-03 | Chu Chung K. | TenPercentOwner | Conversion | 177K | price not stated in the filing | not stated | 1.2M |
| 2020-11-03 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Conversion | 750K | price not stated in the filing | not stated | 5.9M |
| 2020-11-03 | Corcoran Andrea | See Remarks | Conversion | 133K | price not stated in the filing | not stated | 633K |
| 2020-11-03 | BERGER FRANKLIN M | Director | Buy | 42K | $24.00 | $1000K | 820K |
| 2020-11-03 | BERGER FRANKLIN M | Director | Conversion | 760K | price not stated in the filing | not stated | 778K |
| 2020-11-03 | Murphy Polly A. | Director | Conversion | 11K | price not stated in the filing | not stated | 11K |
| 2020-11-03 | Hack Andrew A. F. | Director | Conversion | 5.4M | price not stated in the filing | not stated | 5.4M |
| 2020-11-03 | Hack Andrew A. F. | Director | Buy | 250K | $24.00 | $6.0M | 5.6M |
| 2020-11-03 | Rock Springs Capital Master Fund LP | TenPercentOwner | Conversion | 1.4M | price not stated in the filing | not stated | 1.4M |
| 2020-11-03 | Rock Springs Capital Master Fund LP | TenPercentOwner | Conversion | 282K | price not stated in the filing | not stated | 282K |
| 2020-11-03 | Rock Springs Capital Master Fund LP | TenPercentOwner | Buy | 243K | $24.00 | $5.8M | 1.7M |
| 2020-11-03 | Rock Springs Capital Master Fund LP | TenPercentOwner | Buy | 7K | $24.00 | $175K | 290K |
| 2020-11-03 | Cormorant Asset Management, LP | Other | Conversion | 6.4M | price not stated in the filing | not stated | 6.4M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON6 holders report 5% or more of AVIR in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 15.0% of the class (11,950,772 shares), filed 2026-05-06 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-06 | 13G | KEVIN TANGindividual | 4.8M | 6.0% | 2026-10-06 |
| 2026-10-06 | 13G | TANG CAPITAL MANAGEMENT, LLCother entity | 4.8M | 6.0% | 2026-10-06 |
| 2026-10-06 | 13G | TANG CAPITAL PARTNERS, LPpartnership | 2.5M | 3.1% | 2026-10-06 |
| 2026-10-06 | 13G | TANG CAPITAL PARTNERS INTERNATIONAL, LPpartnership | 1.7M | 2.1% | 2026-10-06 |
| 2026-10-06 | 13G | TANG CAPITAL PARTNERS III, INCcorporation | 661K | 0.8% | 2026-10-06 |
| 2026-10-06 | 13G | TANG CAPITAL PARTNERS IV, INCcorporation | 0 | 0.0% | 2026-10-06 |
| 2026-05-06 | 13G/Ano. 9 | FMR LLCparent holding company | 12.0M | 15.0% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 9 | Abigail P. Johnsonindividual | 12.0M | 15.0% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 3 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-09 | 13G | Leonard Braden Michaelindividual | 7.8M | 9.9% | 2025-12-31 |
| 2026-02-09 | 13G | BML Investment Partners, L.P.partnership | 7.5M | 9.6% | 2025-12-31 |
13F holders
Tracked managers holding AVIR at their latest 13F. JSON6 of the 30 tracked managers held AVIR at their latest 13F, $17.2M in total at quarter-end prices. Two Sigma Investments is the largest at $7.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 1.5M | $7.0M | 0.01% | -357K |
| Renaissance Technologies | 2026-06-30 | 1.1M | $5.3M | 0.01% | -35K |
| D. E. Shaw & Co. | 2026-06-30 | 345K | $1.6M | 0.00% | -34K |
| Millennium Management | 2026-06-30 | 305K | $1.4M | 0.00% | -45K |
| AQR Capital Management | 2026-06-30 | 248K | $1.2M | 0.00% | +202K |
| Citadel Advisors | 2026-06-30 | 157K | $731K | 0.00% | +109K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Atea Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Atea Pharmaceuticals (AVIR), SEC CIK 1593899, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-18.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-06.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-12.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-06-18.JSON and CSV
- Company record
- EDGAR filing index for CIK 1593899Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of AVIR is sold short?
3,070,296 shares were held short at the 2026-10-15 settlement, 10.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is AVIR's daily short volume?
On 2026-11-02, 71,103 of the 103,607 AVIR shares reported to FINRA were sold short, 68.6% of the day's reported volume. Short volume is a flow for one day, not a position.
Does AVIR have fails to deliver?
The SEC's latest file shows 1,237 AVIR shares failed to deliver at settlement 2026-09-18. Fails are reported per settlement date and published twice a month with a lag.
Are AVIR insiders buying or selling?
No open-market insider trades were reported for AVIR in the last 90 days. The most recent filings are listed below. Latest filing: Lucidi Bruno (Director) on 2026-06-18.
Who owns 5% or more of AVIR?
6 holders report 5% or more of AVIR in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 15.0% of the class (11,950,772 shares), filed 2026-05-06 for an event on 2026-03-31.
Which tracked 13F managers own AVIR?
6 of the 30 tracked 13F managers held AVIR shares at their latest filing, $17.2M in all. The largest: Two Sigma Investments (1.5M shares, $7.0M), Renaissance Technologies (1.1M shares, $5.3M), D. E. Shaw & Co. (345K shares, $1.6M), Izzy Englander's Millennium Management (305K shares, $1.4M), Cliff Asness's AQR Capital Management (248K shares, $1.2M), Ken Griffin's Citadel Advisors (157K shares, $731K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.